Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Efficacy and Safety of Scheduled Versus As-Needed Firsekibart Administration for the Prevention of Gout Recurrence: A Multicenter, Open-Label, Randomized Controlled Trial

24. Mai 2026 aktualisiert von: Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Objective To compare the efficacy of continued scheduled dosing versus as-needed dosing in patients with acute gouty arthritis who remained recurrence-free after 24 weeks of treatment with Firsekibart.

Primary Endpoint The proportion of patients experiencing at least one gout recurrence within 24 weeks after randomization.

Secondary Endpoints The mean number of gout recurrences within 24 weeks after randomization;The duration of the first gout recurrence;The proportion of patients experiencing at least one gout recurrence within 12 weeks after randomization;Time to first gout recurrence after randomization;Patient treatment satisfaction at 24 weeks after randomization, assessed using a Likert scale.

Study Design and Methods Patients with acute gouty arthritis who had received Firsekibart as initial treatment and experienced no recurrence during the first 24 weeks of treatment were eligible for enrollment and randomization in this study. Eligible patients were randomized to either a scheduled dosing group or an as-needed dosing group.

In the scheduled dosing group, patients received study treatment immediately after enrollment. In the as-needed dosing group, patients entered an observation period after enrollment and received study treatment only in the event of recurrence.

During the study, gout recurrence was recorded using patient diary cards. Telephone follow-up was conducted every 4 weeks to confirm recurrence status. On-site visits were performed at Weeks 12 and 24, as well as at the time of gout recurrence, for collection of efficacy-related assessments. Adverse events (AEs) and serious adverse events (SAEs) were followed until 12 weeks after the last dose of study drug.

Treatment Arms Scheduled Dosing Group (Intervention Group): Firsekibart 200 mg was administered by subcutaneous injection on the day of randomization.

As-Needed Dosing Group (Control Group): Patients were observed after randomization. If recurrence occurred, patients were required to return to the hospital within 4 days and receive Firsekibart 200 mg by subcutaneous injection.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

118

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

  • China
      • Fuzhou, China
        • Fuzhou University Affiliated Provincial Hospital
        • Kontakt:
          • Fei Gao
          • Telefonnummer: 0086-13665013469
      • Hangzhou, China
        • Zhejiang Hospital
        • Kontakt:
          • Fang Yuan
          • Telefonnummer: 0086-18072963566
      • Hangzhou, China
        • Tongde Hospital of Zhejiang Province
        • Kontakt:
          • Qin Chen
      • Huzhou, China
        • Changxin People's Hospital
        • Kontakt:
          • Yingying Wang
          • Telefonnummer: 0086-13705790575
      • Jinhua, China
        • Jinhua Municipal Central Hospital
        • Kontakt:
          • Li Hua
          • Telefonnummer: 0086-13758992315
      • Ningbo, China
        • Ningbo Medical Center Lihuili Hospital
        • Kontakt:
          • Li Zhou
          • Telefonnummer: 0086-13858287828
      • Wenzhou, China
        • The Second Affiliated Hospital of Wenzhou Medical University
        • Kontakt:
          • Hong Wang
          • Telefonnummer: 0086-13957756514
      • Wenzhou, China
        • The First People's Hospital of Wenlin
        • Kontakt:
          • Yongjun Chen
          • Telefonnummer: 0086-13958633696
    • Zhejiang
      • Hangzhou, Zhejiang, China
        • Zhejiang Provincial People's Hospital
        • Kontakt:
          • Lijuan Wang
          • Telefonnummer: 0086-13567134447
      • Hangzhou, Zhejiang, China
        • The Second Affiliated Hospital Zhejiang University School of Medicine
        • Kontakt:
      • Hangzhou, Zhejiang, China
        • The Second Affiliated Hospital of Zhejiang Chinese Medical University
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  1. Age 18 to 75 years (inclusive), male or female;**
  2. Meet the 2015 ACR/EULAR Gout Classification Criteria;**
  3. Received initial treatment with Firsekibart 200 mg via subcutaneous injection for 24 weeks, and experienced no gout flares during this 24-week period;**
  4. Had≥2 gout flares within 1 year prior to the first administration of Firsekibart；

  5. Willing to comply with the protocol-defined urate-lowering therapy (ULT) during the study, meeting one of the following conditions:

    • Patients currently receiving ULT with a stable regimen for≥14 days may continue their stable dosing; adjustments (including medication switch, dose reduction, or discontinuation) are permitted if the investigator assesses intolerance, poor efficacy, or achievement of target serum uric acid levels;

      • For patients not on ULT or those on ULT but not stable for 14 days before enrollment, the investigator will decide whether to initiate ULT based on uric acid levels. In principle, allopurinol-naive patients should not be prescribed allopurinol in this study;
  6. Voluntarily signed the Informed Consent Form (ICF).

Exclusion Criteria:

  1. History of hypersensitivity to the study drug or similar classes of drugs;
  2. Systemic treatment with corticosteroids, or use of colchicine/NSAIDs within 24 weeks prior to enrollment;
  3. Confirmed active visceral bleeding, or severe bleeding tendency, or currently receiving anticoagulation therapy with heparin;
  4. Confirmed secondary gout;
  5. Confirmed or suspected rheumatoid arthritis, infectious/septic arthritis, or other conditions that may confound the assessment of affected joints (e.g., other joint pain including but not limited to neurological disorders, herpes zoster, etc.);
  6. Presence of infection requiring systemic treatment within 7 days prior to screening;
  7. Received live or live-attenuated vaccines within 3 months prior to screening, or planned vaccination with such vaccines during the study;
  8. History of malignancy within 5 years prior to screening, except for adequately treated or excised cutaneous basal cell carcinoma or Stage I squamous cell carcinoma;
  9. History of systemic irradiation or total lymphoid irradiation; history of stem cell therapy or any type of bone marrow transplantation; history of solid organ transplantation; or long-term systemic use of immunosuppressants;
  10. History of severe immunodeficiency, including positive human immunodeficiency virus (HIV) antibody, or other acquired or congenital immunodeficiency diseases;

  11. History of clinically significant diseases, including:

    Chronic congestive heart failure (NYHA Class IV); History of echocardiography-confirmed ejection fraction (EF) < 30%; Myocardial infarction, acute coronary syndrome, viral myocarditis, or pulmonary embolism within 6 months; Coronary revascularization within 6 months; Severe arrhythmia requiring treatment with Class Ia or III antiarrhythmic drugs; History of sick sinus syndrome, Mobitz II and Complete Heart Block without a permanent pacemaker implanted; QTc interval≥480 ms on screening ECG ;

  12. Confirmed active tuberculosis infection;
  13. Receiving renal dialysis;

  14. Laboratory abnormalities at screening as follows:

    White blood cellcount or absolute neutrophil count below the lower limit of normal at the study site; Platelet count ≤100×10^9/L; Total bilirubin > 1.5 times ULN (Upper Limit of Normal); AST/ALT > 3 times ULN; Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m²; Triglycerides > 5.7 mmol/L;

  15. Pregnant or breastfeeding women;
  16. Women of childbearing potential who refuse to use highly effective contraception during the study;
  17. Use of any investigational drug or participation in other interventional clinical trials within 1 month prior to screening (participation in observational studies only is permitted);
  18. History of drug and/or alcohol abuse or psychiatric disorders;
  19. Any other conditions that, in the opinion of the investigator, may affect the evaluation of efficacy or safety in this study.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Regular dosing group
Arzneimittel: Scheduled Firsekibart administration
A 200 mg subcutaneous injection of Firsekibart will be administered on the day of randomization or the day of gout flare.
Sonstiges: On-demand dosing group
Arzneimittel: As-Needed Firsekibart Administration
Following randomization, patients will remain under continuous observation. In the event of recurrence, patients should return to the hospital within 4 days to receive a 200 mg subcutaneous injection of Firsekibart.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
The proportion of patients experiencing at least one gout recurrence within 24 weeks after randomization.
Zeitfenster: 24 weeks after randomization
24 weeks after randomization

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
Mean number of gout flares over 24 weeks after randomization.
Zeitfenster: 24 weeks after randomization
24 weeks after randomization
Time to resolution of the first gout flare
Zeitfenster: 24 weeks after randomization.
24 weeks after randomization.
Time to first gout flare
Zeitfenster: 24 weeks after randomization
24 weeks after randomization
Proportion of patients with at least one gout flare
Zeitfenster: 24 weeks after randomization
24 weeks after randomization
Patient treatment satisfaction scores
Zeitfenster: 24 weeks after randomization
24 weeks after randomization
Incidence of adverse events and serious adverse events.
Zeitfenster: 24 weeks after randomization
24 weeks after randomization

Andere Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
Change from baseline in CRP and hsCRP
Zeitfenster: 24 weeks after randomization
24 weeks after randomization
Change from baseline in IL-6、IL-1β and TNF-α
Zeitfenster: 24 weeks after randomization
24 weeks after randomization
Change from baseline in ESR
Zeitfenster: 24 weeks after randomization
24 weeks after randomization
Percentage change from baseline in tophus diameter
Zeitfenster: 24 weeks after randomization
24 weeks after randomization
change from baseline in serum urate
Zeitfenster: 24 weeks after randomization
24 weeks after randomization
Pain VAS score at the first gout flare
Zeitfenster: 24 weeks after randomization
24 weeks after randomization

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Mai 2026

Primärer Abschluss (Geschätzt)

28. Februar 2029

Studienabschluss (Geschätzt)

28. Februar 2030

Studienanmeldedaten

Zuerst eingereicht

24. Mai 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

24. Mai 2026

Zuerst gepostet (Tatsächlich)

1. Juni 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

1. Juni 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

24. Mai 2026

Zuletzt verifiziert

1. März 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 20260160

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren